Vaxcyte (PCVX) Liabilities and Shareholders Equity (2019 - 2026)

Vaxcyte (PCVX) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $3.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 0.88% year-over-year to $3.3 billion; the TTM figure through Mar 2026 stood at $12.8 billion (up 2.33% YoY), while the FY2025 annual figure was $3.0 billion, down 14.48% from the prior year.
• Liabilities and Shareholders Equity rose to $3.3 billion in Q1 2026 per PCVX's latest filing, from $3.0 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $3.6 billion in Q3 2024 and bottomed at $402.7 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.1 billion across 5 years, with a median of $2.1 billion in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity jumped 265.1% — and 2025, when it decreased 14.48%.
• Vaxcyte's Liabilities and Shareholders Equity stood at $1.0 billion in 2022, then jumped by 39.93% to $1.4 billion in 2023, then soared by 149.4% to $3.5 billion in 2024, then fell by 14.48% to $3.0 billion in 2025, then increased by 11.51% to $3.3 billion in 2026.
• Business Quant data shows PCVX's Liabilities and Shareholders Equity at $3.3 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.2 billion in Q3 2025.